ClinicalTrials.gg
RecruitingNCT05558501Updated Dec 4, 2025

Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities

A Phase 1/2 interventional study of Mild Intermittent Hypoxia and Sham MIH in Obstructive Sleep Apnea, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by VA Office of Research and Development · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development — 7 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · VA Office of Research and Development.

Planned enrollment
13th of 22
60 · median 92
Started
2023
with 2 others
Phase 1/2
2 of 24
2 open now
Registered
21st of 24
by date

Among the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 1/2, and was the 21st registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

7 of the 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Sleep Apnea, Obstructive by VA Office of Research and Development, or all of them as a file.
02

Study summary

The prevalence of obstructive sleep apnea (OSA) is high in the United States and is a major health concern. This disorder is linked to numerous heart, blood vessel and nervous system abnormalities, along with increased tiredness while performing exercise likely because of a reduced blood supply to skeletal muscles. The gold standard treatment of OSA with continuous positive airway pressure (CPAP) in many cases does not lead to significant improvements in health outcomes because the recommended number of hours of treatment per night is often not achieved. Thus, development of novel treatments to eliminate apnea and lessen the occurrence of associated health conditions is important. The investigators will address this mandate by determining if repeated exposure to mild intermittent hypoxia (MIH) reduces heart and blood vessel dysfunction and tiredness/ fatigue experienced while exercise performance. The investigators propose that exposure to MIH has a multipart effect. MIH directly targets heart and blood vessel associated conditions, while simultaneously increasing upper airway stability and improving sleep quality. These modifications may serve to directly decrease breathing episodes and may also serve to improve usage of CPAP. Independent of its effect, MIH may serve as an adjunctive therapy which provides another path to reducing heart and blood vessel abnormalities that might ultimately result in improvements in exercise capacity and reverse performance fatigue in individuals with OSA.

Read the detailed description

The prevalence of obstructive sleep apnea (OSA) is high in the Veteran population and this disorder is linked to numerous cardiovascular, neurocognitive and metabolic abnormalities. Thus, OSA is a major health concern in the Veteran population. Treatment of OSA in many cases does not lead to significant improvements in outcome measures. This inadequacy may be a consequence of reduced treatment adherence with continuous positive airway pressure (CPAP) or because the effect of CPAP on outcome measures is small or absent in some patients despite adequate adherence. Consequently, innovative therapies that directly impact co-morbidities linked to OSA or that increase CPAP adherence could lead to improved outcome measures. In the recent funding cycle, the investigators established that repeated daily exposure to mild intermittent hypoxia (MIH) coupled with CPAP modifies autonomic nervous system activity and dramatically decreases blood pressure compared to CPAP treatment alone. Because MIH was coupled with CPAP, the independent effect of MIH on blood pressure was not established. Moreover, it was not established if these outcomes were sustained for a prolonged time period (i.e. weeks to months).

Although the investigators obtained some indirect evidence that modifications in autonomic nervous system activity were coupled to the reduction in blood pressure, the investigators did not establish if modifications in microvascular function were evident. Microvascular dysfunction together with sympatho-vagal imbalance may have consequences not only for peripheral vascular resistance and blood pressure but also for muscle perfusion and metabolism, thereby limiting exercise performance and increasing fatigability in patients with OSA. Thus, reductions in blood pressure and improvement in microvascular function following treatment with MIH might serve to improve exercise capacity and reverse performance fatigue in individuals with OSA.

Besides its potential effect on autonomic and cardiovascular function, the investigators and others previously established that acute exposure to MIH initiates sustained increases in upper airway muscle activity in humans. This sustained increase is a form of respiratory plasticity known as long-term facilitation. However, in the absence of CPAP the investigators have shown that acute MIH immediately prior to or during sleep leads to increases in apnea severity. This might occur because the manifestation of long-term facilitation is absent in the presence of hypocapnia. Hypocapnia can be induced during sleep by the initiation of another form of plasticity known as progressive augmentation. However, it is possible that the combination of daily exposure to MIH administered many hours before the sleep period may mitigate the effects of progressive augmentation leading to increased upper airway stability.

Independent of this possibility, the investigators showed in the previous funding cycle that increased upper airway stability following treatment with MIH was coupled to a reduction in therapeutic CPAP and improved adherence. However, improved adherence to CPAP might also be linked to an increase in the arousal threshold to both respiratory and non-respiratory stimuli. All the uncertainties outlined above will be addressed in the present proposal.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Intermittent Hypoxia
  • Microvascular Function
  • Fatigability
  • Maximal Oxygen Consumption
  • Sympatho-Vagal Balance
  • CPAP Adherence
  • Arousal Threshold
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of any race, 30-60 years of age with a of less than 40 kg/m2 and a weight to hip ratio of less than 1.3in males and 1.2 in females along with pure or predominantly (i.e., comprised of both a central and obstructive component)OSA (AHI less than or equal to 100 events per hour and an average oxygen desaturation level of 85 % or greater).
  • Participants will be newly diagnosed and not previously treated with CPAP.
  • Participants will also be diagnosed with hypertension. Participants will either be untreated or will be treated unsuccessfully with a single prescribed medication for hypertension. Hypertension will be classified according to the American Heart Association 2018 criteria which includes an elevated systolic blood pressure in the range of 120-129 and a diastolic pressure less than 80 mmHg in addition to stage I and stage II hypertension defined by a systolic blood pressure greater than 130 mmHg and a diastolic pressure greater than 80 mmHg.
  • Participants will also be included if they are pre-diabetic (: 5.7 - 6.4 %; fasting blood glucose: 100 - 125 mg/dL) and have cholesterol levels ranging from 200-239 mg/dL.
  • All participants will have normal lung function and a normal with no or minimal alcohol consumption (\< 2 oz of alcohol/night).
  • Females will be studied at similar points in their menstrual cycle.

Exclusion criteria

Exclusion Criteria:

  • Participants with baseline blood pressure greater than 160/110 will be excluded from participation.
  • Participants on any medications, with the exception of a single prescribed medication for individuals with resistant hypertension.
  • Participants with any other known disease (e.g. pulmonary hypertension).
  • Participants using any sleep promoting supplements including melatonin.
  • Night shift workers or participants who recently travelled across time zones.
  • Pregnant females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Mild Intermittent Hypoxia (MIH)

    This arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory.

    Other: Mild Intermittent Hypoxia

  • Sham comparator
    Sham Mild Intermittent Hypoxia (Sham MIH)

    This arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory.

    Other: Sham MIH

Interventions

  • OtherMild Intermittent Hypoxia

    The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.

  • OtherSham MIH

    During "sham MIH" the participants will be exposed to compressed air (the equivalent of room air).

06

What researchers measure

Primary outcomes

  1. Change in Blood Pressure

    Blood pressure measures over 24 hours will be obtained. Blood pressure will be measured every 20 minutes beginning on Sunday at 6 AM and ending Monday at 6 AM. Participants will wear an actigraph (Actiwatch Spectrum, Respironics) and record their activities in a journal to determine the arousal state (i.e., active wakefulness, quiet wakefulness and sleep) associated with each blood pressure measurement. The data will be separated into active-awake, rest-awake and sleep based on the activity log and corresponding data from an actigraph watch. The average value of blood pressure in a healthy individual is 120/80 mmHg. In their participants with OSA, the investigators expect the blood pressure to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

  2. Change in Microvascular Function (Maximal hyperemic Response)

    Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the maximal hyperemic response (MHR) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg. The average value of TSI MHR of the NIRS signals in healthy individuals is 159±9 %. In their participants with OSA, the investigators expect these values to be lower at baseline and to increase 15 days after treatment. The investigators also expect that the increase will be maintained 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

  3. Change in Microvascular Function (Time to reach Maximal Hyperemic Response)

    Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the time to reach maximal hyperemic response (tM) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg. The average value of tM TSI in healthy individuals is 39±5 s. In their participants with OSA, the investigators expect these values to be higher at baseline and to lower 15 days after treatment. The investigators also expect that the decrease will be maintained 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

Secondary outcomes

  1. Change in Muscle Oxygen Extraction (Time Delay)

    Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variables i.e. time delay of \[HHb\] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line. The average reported value of \[HHb\] time delay in a healthy individual is 14.8±1.6s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.

    Time frame: Change at 15 days following treatment compared to baseline

  2. Change in Muscle Oxygen Extraction (Mean Response Time)

    Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variables i.e. mean response time of \[HHb\] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line. The average reported value of \[HHb\] mean response time in a healthy individual is 27.2±2.9s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.

    Time frame: Change at 15 days following treatment compared to baseline

  3. Change in Sympatho-Vagal Balance (Blood Pressure Variability)

    Blood pressure variability will be assessed non-invasively using beat to beat measures of blood pressure. The ratio of low frequency and high frequency range (LF-HF ratio) obtained from the power spectrum analysis of blood pressure variability is considered representative of sympathetic to parasympathetic balance in both physiological and pathophysiological conditions. The normal range of LF-HF ratio in a healthy individual is 1.5-2. In their participants with OSA, the investigators expect the ratio to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

  4. Change in Muscle Oxygen Extraction (Tau)

    Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variable i.e. tau of \[HHb\] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line. The average reported value of \[HHb\] tau in a healthy individual is 12.4±2.2s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.

    Time frame: Change at 15 days following treatment compared to baseline

  5. Change in Maximal Oxygen Consumption

    All the participants will complete a maximum oxygen consumption (VO2 max) test using a treadmill. Continuous monitoring of electrical activity of the heart with an electrocardiogram along with the measurement of breath by breath oxygen consumption and carbon dioxide production will be performed. The average value of VO2 max in a healthy individual is 35-40 mL/kg/min. In their participants with OSA, the investigators expect the maximal oxygen consumption to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

  6. Change in Fatigability

    Participants will perform a 10-minute walk test on a 25 m indoor walking course at the beginning and end of the protocol. The distance covered will be recorded every 2.5 minutes and at the end of 10 minutes. The ratio of the average walking speed calculated over the entire 10 minutes of walking and the walking velocity calculated over the first 2.5 minutes of the test will be computed. This ratio will then be normalized to the total distance covered in 10 minutes to calculate the performance fatigability index. The average value of performance fatigability index in a healthy individual is less than 1. In the participants with OSA, the investigators expect the performance fatigability index to be higher at baseline and reduce 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

  7. Change in Sympatho-Vagal Balance (Heart Rate Variability)

    Heart rate variability will be assessed non-invasively using beat to beat measures of heart rate. The ratio of low frequency and high frequency range (LF-HF ratio) obtained from the power spectrum analysis of heart rate variability is considered representative of sympathetic to parasympathetic balance in both physiological and pathophysiological conditions. The average value of LF-HF ratio in a healthy individual is 1.6±1. In their participants with OSA, the investigators expect the ratio to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

Other outcomes

  1. Change in CPAP Adherence

    CPAP adherence will be assessed by documenting the number of hours of CPAP used per night. The average value of CPAP adherence in an individual with OSA is 3.92±0.65 hours per night. In our participants with OSA, the investigators expect the ratio to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8-weeks following treatment compared to baseline

  2. Change in Arousal Threshold

    Arousal threshold to respiratory and non-respiratory (tactile and auditory) stimuli will be measured during baseline polysomnographic and CPAP titration night studies. The average value of tone-induced arousal threshold in an individual with OSA is 64.5±2.2 dB. In our participants with OSA, the investigators expect the dB level to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline

  3. Change in Sleep Apnea Severity

    Sleep apnea severity will be determined from the apnea hypopnea index obtained from overnight polysomnographic studies. The average value of the apnea hypopnea index in a healthy individual is less than 5 events per hour. In our participants with OSA, we expect the index to be higher at baseline and decrease 15 days after treatment. We also expect that this reduction will be maintained at 4 and 8-weeks following treatment.

    Time frame: Change at 15 days, 4 and 8-weeks following treatment compared to baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2022
First posted
Sep 28, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05558501
Collaborators
John D. Dingell VA Medical Center
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Jan 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Jason H Mateika, PhD MS BS
Contact
jmateika@med.wayne.edu
(313) 576-4481 ext. 64481
Shipra Puri
Contact
shiprapuri@wayne.edu
(313) 576-1000
Jason H Mateika, PhD MS BS
principal investigator · John D. Dingell VA Medical Center, Detroit, MI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion